



Can-Fite BioPharma Announces the Initiation of Patient Enrolment for the Phase 2/3 Psoriasis Study with its Lead Drug CF101

The study will be conducted in 17 medical centers in the United States, Europe and Israel under an open IND

Petah Tikva, Israel, August 1st 2011: Can-Fite BioPharma (TASE: CFBI) announced today that it has commenced patient enrolment in a phase 2/3 clinical trial of CF101 for the treatment of Psoriasis. This clinical trial will be conducted in 17 medical centers in the United States, Europe and Israel under an open IND.

Prof. Fishman, Chief Executive Officer of Can-Fite: "We are very pleased with this progress and the enthusiasm of all the investigators. The positive data from the previous phase 2 study as well as the excellent safety profile of CF101 indicates the potential of this innovative oral treatment for the treatment of psoriasis".

The planned randomized, double-blind, controlled trial will compare 2 dose levels of CF101 to placebo. Approximately 300 patients will be enrolled at 17 centers, and will be treated for 24 weeks. The main outcome assessments (clinical endpoints) are Physician's Global Assessment, Body Surface Area involvement, and PASI. An interim analysis will be carried out after the 100 first patients.

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd is a public company, trading on the Tel Aviv Stock Exchange. The company, which commenced business activity on 2000, was founded by Prof Pnina Fishman, researcher in the Rabin Medical Center, and Dr Ilan Cohen, patent attorney and senior partner at Reinhold Cohen Patent Attorneys. Prof Fishman serves as CEO of the company. The company was founded on the basis of Prof Fishman's scientific findings, and is focused on the development of small molecule drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. The company's lead drug, CF101, is in advanced clinical development for the treatment of autoimmune inflammatory and ophthalmic diseases. The CF102 drug candidate is being developed for the treatment of liver diseases. Can-Fite has a wealth of clinical experience: to date, more than 700 patients have participated in clinical trials conducted by the company.

For more details:

Jonathan Eilat

054-2681977

03-6868654

